The Fly | BIIB

Biogen

· BIIB

Dashboard

Financials

KPIs

Ratios

Transcripts

Valuation

Thursday

Biogen price target raised by $18 at Morgan Stanley, here's why

BIIB

Jun 18, 6:43 AM

Over a week ago

Biogen to acquire RayThera for up to $1B

BIIB

Jun 17, 7:00 PM

Biogen price target lowered by $15 at Mizuho, here's why

BIIB

Jun 15, 6:58 AM

Needham upgrades Biogen on pipeline potential, stabilizing core business

BIIB

Jun 8, 6:45 AM

Needham gets more bullish on Biogen, upgrades shares

BIIB

Jun 8, 6:32 AM

Biogen granted Breakthrough Therapy Designation for salanersen by FDA

BIIB

Jun 4, 7:33 AM

UCB, Biogen announce dapirolizumab pegol data at EULAR

BIIB

Jun 4, 5:37 AM

Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet

BIIB

Jun 1, 5:52 AM

Biogen price target raised by $5 at RBC Capital, here's why

BIIB

May 27, 8:25 AM

Biogen and Denali's Parkinson's candidate did not meet Phase 2b endpoints

May 21, 6:04 PM

Immunic appoints Michael Bonney as chair

May 19, 6:33 AM

Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls

+12

May 15, 9:45 AM

Biogen resumed with an Outperform at Evercore ISI

BIIB

May 15, 8:18 AM

Biogen price target raised by $11 at Piper Sandler, here's why

BIIB

May 15, 6:33 AM

Biogen CELIA topline readout in Alzheimer's 'historic,' says H.C. Wainwright

May 14, 10:20 AM

Morning Movers: Klarna and Yeti rise following quarterly earnings

May 14, 8:55 AM

Biogen completes acquisition of Apellis Pharmaceuticals

May 14, 8:50 AM

Video: Cisco surges as AI powers better-than-anticipated forecast

May 14, 8:45 AM

Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer's Disease

BIIB

May 14, 7:23 AM

Ionis announces Biogen's CELIA study did not meet primary endpoint

May 14, 7:09 AM

Biogen's diranersen shows benefits in early Alzheimer's Disease

May 14, 7:04 AM

Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA

May 8, 5:15 AM

Remitly Global to replace Apellis in S&P 600 at open on 5/14

May 7, 5:26 PM

Biogen just upgraded at Freedom Broker, here's why

BIIB

May 1, 10:08 AM

Neuroscience Leadership: Biogen possesses deep, specialized expertise and a long-standing focus on developing treatments for neurological and neurodegenerative diseases, allowing for targeted innovation and market leadership in complex therapeutic areas.

Established Product Portfolio: The company benefits from a portfolio of approved and revenue-generating drugs, including treatments for multiple sclerosis (MS) and spinal muscular atrophy (SMA), providing a stable financial base and market presence.

Robust Research and Development Capabilities: Biogen maintains strong internal R&D capabilities, consistently investing in groundbreaking science to discover and advance novel therapies for high-unmet-need neurological conditions.

Clinical Trial and Regulatory Failure Risk: Drug development is inherently risky, with high rates of failure in clinical trials or challenges in securing regulatory approvals for new therapies, leading to substantial R&D expenditure without commercial returns.

Intense Competition Risk: Biogen faces significant competition from other pharmaceutical companies developing treatments for similar conditions, potentially leading to erosion of market share, pricing pressures, and reduced profitability for its key products.

Patent Expiry and Generic Competition Risk: The company's established drugs are subject to patent expirations, which opens the door for generic and biosimilar competition, resulting in significant revenue declines as seen with Tecfidera.